Relmada Therapeutics Terminates Material Agreement
Ticker: RLMD · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination
TL;DR
Relmada terminated a key deal, expect news soon.
AI Summary
Relmada Therapeutics, Inc. announced on July 7, 2025, the termination of a material definitive agreement. The company, incorporated in Nevada, filed this 8-K report on July 10, 2025, detailing the event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial outlook.
Risk Assessment
Risk Level: medium — Termination of a material agreement can signal underlying issues or strategic shifts that may affect the company's future performance.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- July 7, 2025 (date) — Date of earliest event reported
- July 10, 2025 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- 2222 Ponce de Leon Blvd. , Floor 3 Coral Gables , FL 33134 (address) — Principal executive offices
FAQ
What specific material definitive agreement was terminated by Relmada Therapeutics, Inc.?
The filing states that a material definitive agreement was terminated, but does not specify which agreement.
What is the effective date of the termination of the material definitive agreement?
The earliest event reported, which includes the termination, is dated July 7, 2025.
When did Relmada Therapeutics, Inc. file this 8-K report?
Relmada Therapeutics, Inc. filed this 8-K report on July 10, 2025.
Where is Relmada Therapeutics, Inc. incorporated?
Relmada Therapeutics, Inc. is incorporated in Nevada.
What is the business address of Relmada Therapeutics, Inc.?
The business address is 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 regarding RELMADA THERAPEUTICS, INC. (RLMD).